Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TETRIS

Financiado

Cerrado

Risk assessment Tools for severe side Effects after breasT Radiotherapy: radiat...

Risk assessment Tools for severe side Effects after breasT Radiotherapy: radiation safety through biological extended models and dIgital twinS Radiation protection and safety measures are essential to ensure adequate quality & safety in radiotherapy (RT). Side effects are systematically mitigated through optimisation and individualisation.Breast cancer (Bca) is the most... ver más

30/09/2027

INT

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMOR... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-01

HORIZON-EURATOM-2023-NRT-01-04: Co-funded European partnership for... ExpectedOutcome:In line with the objectives of the Nuclear Safety Directive, this European partnersh...

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

INT

Lider

Proyectos interesantes

PRO-ORATICA

Medical Technol...

Data Science

161K€ Cerrado

ASSURE

Medical Technol...

Data Science

7M€ Cerrado

EPI-CT

Medical Technol...

Data Science

7M€ Cerrado

DPI2015-68442-R

Medical Technol...

Data Science

138K€ Cerrado

SINFONIA

Medical Technol...

Data Science

6M€ Cerrado

REQUITE

Medical Technol...

Data Science

8M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 35 meses Fecha Inicio: 2024-10-01
Fecha Fin: 2027-09-30

Líder del proyecto

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMOR... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Radiation protection and safety measures are essential to ensure adequate quality & safety in radiotherapy (RT). Side effects are systematically mitigated through optimisation and individualisation.Breast cancer (Bca) is the most common cancer in women in Europe, leading to millions of BCa survivors in Europe; this group is projected to increase in the next decades. Randomised trials established the role of RT following breast surgery. Careful RT planning and delivery allow targeting the breast while minimising the dose to organs at risk. Yet, some doses unavoidably reach the lung and the heart, putting BCa patients at risk for severe cardiac and pulmonary disease and second cancers. Quantitative personalised risk scores for late severe cardiac/pulmonary disease/second cancers following RT would reveal opportunities to further mitigate the risk of side effects at the individual patient level. Risk scores would provide a quantitative guide when shaping the patients’ follow-up and screening program to assess the risk or presence of subclinical diseases.Within TETRIS, we propose to design and test quantitative personalised low-level risk scores based on dose-response relationships already published in the literature and refined risk scores which merge patient-specific features (from imaging, genetics and transcriptomics) with RT dose.The project also proposes to explore the opportunities and challenges of applying digital twins (DTs) in RT safety. We will use the historical cohort to develop the prototypes and evaluate the gain we can have using digital twins for risk assessment instead of model-based risk scores. Using a prospective collection of detailed patient data, we will demonstrate the possibility of refining DTs, allowing a deeper description of the single patient and a broader description of the patient’s follow-up. The value of the refined DTs could shape investments in data collection and computational resources for radioprotection.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores